Hepion Pharmaceuticals, Inc. – NASDAQ:HEPA
Hepion Pharmaceuticals stock price today
$0.053
-0.40
-88.59%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 minutes
Hepion Pharmaceuticals stock price monthly change
-57.01%
month
Hepion Pharmaceuticals stock price quarterly change
-57.01%
quarter
Hepion Pharmaceuticals stock price yearly change
-87.19%
year
Hepion Pharmaceuticals key metrics
Market Cap | 3.47M |
Enterprise value | N/A |
P/E | -1.28 |
EV/Sales | N/A |
EV/EBITDA | 0.05 |
Price/Sales | N/A |
Price/Book | 0.95 |
PEG ratio | 0.02 |
EPS | -9.4 |
Revenue | N/A |
EBITDA | -37.11M |
Income | -38.51M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHepion Pharmaceuticals stock price history
Hepion Pharmaceuticals stock forecast
Hepion Pharmaceuticals financial statements
| Jun 2023 | 0 | -14.07M | |
|---|---|---|---|
| Sep 2023 | 0 | -10.52M | |
| Dec 2023 | 109.73K | -11.05M | -10078.95% |
| Mar 2024 | 0 | -2.85M |
| 2027 | 0 | -37.16M |
|---|
Analysts Price target
Financials & Ratios estimates
| 2022-08-15 | -0.12 | -0.26 |
|---|---|---|
| 2022-11-14 | -0.17 | -0.11 |
| Jun 2023 | 36502110 | 10.12M | 27.75% |
|---|---|---|---|
| Sep 2023 | 25003108 | 8.84M | 35.37% |
| Dec 2023 | 18094397 | 10.81M | 59.76% |
| Mar 2024 | 15989411 | 8.46M | 52.96% |
| Jun 2023 | -12.43M | -16.53K | 0 |
|---|---|---|---|
| Sep 2023 | -11.23M | 2.58K | 0 |
| Dec 2023 | -9.00M | -348 | 4.49M |
| Mar 2024 | -3.61M | 0 | 1.84M |
Hepion Pharmaceuticals alternative data
| Aug 2023 | 25 |
|---|---|
| Sep 2023 | 25 |
| Oct 2023 | 25 |
| Nov 2023 | 25 |
| Dec 2023 | 25 |
| Jan 2024 | 25 |
| Feb 2024 | 25 |
| Mar 2024 | 25 |
| Apr 2024 | 25 |
| May 2024 | 22 |
| Jun 2024 | 22 |
| Jul 2024 | 22 |
Hepion Pharmaceuticals other data
3.12%
-6.25%
of HEPA is owned by hedge funds
16
-11
2.37M
-4.76M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 4200 | 0 |
| Nov 2023 | 5000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | WIJNGAARD PETER director | Common Stock | 2,500 | $3.05 | $7,625 | ||
Purchase | WIJNGAARD PETER director | Common Stock | 2,500 | $3.09 | $7,725 | ||
Purchase | WIJNGAARD PETER director | Common Stock | 1,000 | $5.64 | $5,640 | ||
Purchase | FOSTER ROBERT T director, officer: CEO and Dire.. | Common Stock | 1,600 | $5.6 | $8,960 | ||
Purchase | FOSTER ROBERT T director, officer: CEO,CSO and .. | Common Stock | 1,600 | $5.4 | $8,640 | ||
Purchase | FOSTER ROBERT T director, officer: CEO and Dire.. | Common Stock | 20,000 | $2 | $40,000 | ||
Purchase | CAVAN JOHN T officer: Chief Fi.. | Common Stock | 10,000 | $2 | $20,000 | ||
Purchase | WIJNGAARD PETER director | Common Stock | 10,000 | $2.2 | $22,000 | ||
Purchase | WIJNGAARD PETER director | Common Stock | 20,000 | $1.91 | $38,200 | ||
Purchase | FOSTER ROBERT T director, officer: CEO and Dire.. | Common Stock | 25,000 | $1.58 | $39,425 |
| Patent |
|---|
Application Filling date: 26 Nov 2021 Issue date: 2 Jun 2022 |
Application Filling date: 24 Feb 2021 Issue date: 2 Sep 2021 |
Application Filling date: 19 Feb 2021 Issue date: 26 Aug 2021 |
Application Filling date: 22 Nov 2019 Issue date: 28 May 2020 |
| Insider | Compensation |
|---|---|
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. (1958) Pres, Chief Executive Officer & Director | $600,000 |
| Mr. John T. Cavan (1958) Chief Financial Officer | $406,250 |
-
What's the price of Hepion Pharmaceuticals stock today?
One share of Hepion Pharmaceuticals stock can currently be purchased for approximately $0.05.
-
When is Hepion Pharmaceuticals's next earnings date?
Unfortunately, Hepion Pharmaceuticals's (HEPA) next earnings date is currently unknown.
-
Does Hepion Pharmaceuticals pay dividends?
No, Hepion Pharmaceuticals does not pay dividends.
-
How much money does Hepion Pharmaceuticals make?
Hepion Pharmaceuticals has a market capitalization of 3.47M. Hepion Pharmaceuticals made a loss 48.93M US dollars in net income (profit) last year or -$0.11 on an earnings per share basis.
-
What is Hepion Pharmaceuticals's stock symbol?
Hepion Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "HEPA".
-
What is Hepion Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Hepion Pharmaceuticals?
Shares of Hepion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Hepion Pharmaceuticals's key executives?
Hepion Pharmaceuticals's management team includes the following people:
- Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. Pres, Chief Executive Officer & Director(age: 67, pay: $600,000)
- Mr. John T. Cavan Chief Financial Officer(age: 67, pay: $406,250)
-
How many employees does Hepion Pharmaceuticals have?
As Jul 2024, Hepion Pharmaceuticals employs 22 workers, which is 12% less then previous quarter.
-
When Hepion Pharmaceuticals went public?
Hepion Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 10 Feb 2014.
-
What is Hepion Pharmaceuticals's official website?
The official website for Hepion Pharmaceuticals is hepionpharma.com.
-
Where are Hepion Pharmaceuticals's headquarters?
Hepion Pharmaceuticals is headquartered at 399 Thornall Street, Edison, NJ.
-
How can i contact Hepion Pharmaceuticals?
Hepion Pharmaceuticals's mailing address is 399 Thornall Street, Edison, NJ and company can be reached via phone at +7 329024000.
Hepion Pharmaceuticals company profile:
Hepion Pharmaceuticals, Inc.
hepionpharma.comExchange:
NASDAQ
Full time employees:
22
Industry:
Biotechnology
Sector:
Healthcare
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
399 Thornall Street
Edison, NJ 08837
Edison, NJ 08837
CIK: 0001583771
ISIN: US4268973025
CUSIP: 426897104
